6-MAPBT, also known as 6-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families related to MDMA.
It acts as a monoamine releasing agent and serotonin receptor modulator. The drug's values for monoamine release are 57nM for serotonin and 71nM for dopamine. It is also a potent agonist of the serotonin 5-HT1B receptor, with an of 24nM, and is a potent antagonist of the serotonin 5-HT2B receptor, with an of 72nM. Conversely, it is far weaker as an agonist of the serotonin 5-HT2A receptor ( = 959nM) and is inactive at the serotonin 5-HT1A receptor. In addition to the preceding actions, the drug is a monoamine oxidase A (MAO-A) inhibitor, with an of 945nM.
It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents. However, benzothiophenes like 6-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents.
6-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen. The drug has also been patented by Mydecine and given the developmental code name MY300.
See also Substituted benzothiophene 5-MAPBT
References
External links 6-MAPBT - Isomer Design